Renal osteodystrophy: Past and present

Seminars in Dialysis

Volumn 9, Issue 4, 1996, Pages 296-301

  Antonsen, John E ^a   Sherrard, Donald J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 17944381816     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139x.1996.tb00680.x     Document Type: Article

References (63)

1. Liu SH, Chu HI: Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T.10) and iron. Medicine 22:103-161, 1943
2. Virchow R: Kalk-Metastasen. Arch Pathol Anat Physiol 8:103-107, 1877
3. Lucas RC: On a form of late rickets associated with albuminuria, rickets of adolescents. Lancet 1:993-994, 1883
4. Parsons, LG: The bone changes occurring in renal and coeliac infantilism, and their relation to rickets: I. Renal rickets: Arch Dis Child 2:1, 1927
5. Follis RH Jr, Jackson DB: Renal osteomalacia and osteitis fibrosa in adults. Bull Johns Hopkins Hosp 72:232-242, 1943
6. Gilmour, JR: The parathyroid glands and skeleton in renal disease. London, Oxford University Press, 1947
7. Albright F, Drake TG, Sulkowitch HW: Renal osteitis fibrosa cystica. Bull Johns Hopkins Hosp 60:377, 1937
8. Dreskin EA, Fox TA: Adult renal osteitis fibrosa with metastatic calcification and hyperplasia of one parathyroid gland. Arch Int Med 86:533, 1950
9. Stanbury, SW: Azotaemic renal osteodystrophy. Brit Med Bull 13: 57-60, 1957
10. Johnson C, Graham CB, Curtis FK: Roentgenographic manifestations of chronic renal disease treated by periodic hemodialysis. Am J Roentgenol 101:915-926, 1967
11. Freeman S and Freeman WMC: Phosphorus retention in children with chronic renal insufficiency. Amer J Dis Child 61:981, 1941
12. Lindholm T: Oral aluminum hydroxide in the treatment of hyperphosphatemia and acidosis in acute and renal insufficiency. Acta Med Scan 172:75-78, 1962
13. Sherrard DJ, Baylink DJ, Wergedal JE, Maloney N: Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endo Metab 39:119-135, 1974
14. Evanson JM: The response to the infusion of parathyroid extract in hypocalcemic states. Clin Sci 31:63-75, 1966
15. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 78:357-64, 1973
16. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endo Metab 41:339-345, 1975
17. Bricker NS, Slatopolsky E, Reiss E, Avioli LV: Calcium, phosphorus and bone in renal disease and transplantation. Arch Int Med 123:543-553, 1969
18. Bricker NS: On the pathogenesis of the uremic state: An exposition of the "trade-off" hypothesis. N Engl J Med 286:1093-1099, 1972
19. Stanbury SW: Osteodystrophy developing spontaneously in the course of chronic renal failure. Arch Int Med 124:274-281, 1969
20. Lawson DEM, Fraser DR, Kodicek E, Morris HR, Williams OH: Identification of 1,25 dihydroxy-cholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230:228-230, 1971
21. Brickman AS, Jowsey J, Sherrard DJ, Singer FR, Baylink DJ, Maloney N, Massry SG, Norman AW, Coburn JW: 1,25 dihydroxy-cholecalciferol in uremic osteodystrophy. Arch Intern Med 134:883-888, 1974
22. 3 in uremic patients. J Clin Invest 74:2136-2142, 1984
23. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
24. Portale AA, Halloran BP, Morris RC Jr: Physiologic regulation of the serum concentration of 1,25 dihydroxyvitamin D by phosphorus in normal man. J Clin Invest 83:1494-9, 1989
25. Yi H, Fukagawa M, Kurokawa K: Mild dietary phosphorus restriction directly prevents enhanced parathyroid hormone secretion and synthesis and proliferation of parathyroid cells in chronic renal failure in rats. J Am Soc Nephrol 3:703, 1992
26. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald P, Brown A: Phosphate restriction preventions parathyroid cell growth in uremic rats and high phosphate directly stimulated PTH secretion in tissue culture. J Am Soc Nephrol (abstract) 6:971, 1995
27. Almaden Y, Hernandez A, Torregrossa V, Campistol J, Torres A, Rodriguez M: High phosphorus directly simulates PTH secretion by human parathyroid tissue. J Am Soc Nephrol (abstract) 6:957, 1995
28. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN: Fracturing osteodystrophy and dialysis encephalopathy: An epidemiological survey. Lancet 1:406-109, 1979
29. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DNS, Herrington J, Goode GL: Osteomalacic dialysis osteodystrophy: Evidence for a water-borne etiological agent, probably aluminum. Lancet 1:841-845, 1978
30. Alfrey AC, Hegg A, Craswell P: Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 33:1509-1516, 1980
31. Ott SM, Maloney NA, Coburn JW, Alfrey AC, Sherrard DJ: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 307: 709-714, 1982
32. Andress DL, Maloney NA, Endres DB, Sherrard DJ: Aluminum-associated bone disease in chronic renal failure: High prevalence in a long-term dialysis population. J Bone Miner Res 1:391-398, 1986
33. Llach F, Felsenfeld AJ, Coleman MD: The natural course of dialysis osteomalacia. Kidney Int 29 (Suppl 18):S74-S79, 1986
34. Morrissey J, Rothstein M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone secretion by aluminum. Kidney Int 23:699-704, 1983
35. Blumenthal NC, Posner AS: In vitro model of aluminum-induced osteomalacia: Inhibition of hydroxyapatite formation and growth. Calcif Tissue Int 36:439-441, 1984
36. Goodman WG, Henry DA, Horst R, Hudelman RK, Alfrey AC, Coburn JW: Parenteral aluminum administration in the dog. II. Induction of osteomalacia and effect on vitamin D metabolism. Kidney Int 25:370-375, 1984
37. 3 metabolites. Calcif Tissue Int 34:280-284, 1982
38. Andress DL, Maloney NA, Coburn JW, Endres DB, Sherrard DJ: Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. J Clin Endocrinol Metab 65:11-6, 1987
39. Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, Coburn JW, Sherrard DJ: Bone histologic response to deferoxamine in aluminum-related bone disease: Kidney Int 31:1344-1350, 1987
40. Windus DW, Stokes TJ, Julian BA, Fenves AZ: Fatal rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 107:678-680, 1987
41. Anthone S, Ambrus CM, Kohli R, Min I, Anthone R, Stadler A, Stadler I, Vladutiu A: Treatment of aluminum overload using a cartridge with immobilized desferrioxamine. J Am Soc Neph 6:1271-1277, 1995
42. Jouhanneau P, Lacour B, Raisbeck G, Yiou F, Banide H, Brown E, Drucke T: Gastrointestinal absorption of aluminum in rats using 26AI and accelerator mass spectrometry. Clin Nephrol 40:244-248, 1993
43. Andress DL, Kopp JB, Maloney NA, Coburn JW, Sherrard DJ: Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 316:292, 1987
44. Andreoli SP, Bergstein JM, Sherrard DJ: Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310:1079-1084, 1984
45. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end stage renal failure - an evolving disorder. Kidney Int 43:436-442, 1993
46. Morrissey J, Rothstein M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone by aluminum. Kidney Int 23:699-706, 1983
47. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
48. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721, 1994
49. Fischer ER, Harris CH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40:216-220, 1993
50. 3H) 1,25-dihydroxyvitamin D in patients with renal failure. N Engl J Med 316:1573-1577, 1987
51. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1432-1443, 1993
52. Sherrard DJ, Baylink D, Wergedal J: Bone disease in uremia. ASAIO Trans 28:412-415, 1972
53. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
54. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kid Dis 26:836-844, 1995
55. Suda T, Takahashi N, Martin TJ: Modulation of osteoclast differentiation. Endocrine Rev 13:66-80, 1992
56. McSheehy PMJ, Chambers TJ: Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. Endocrinology 119:1654-1659, 1986
57. Pfeilschifter J, Seyedin SM, Mundy GR: Transforming growth factor β inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 82:680-685, 1988
58. MacDonald BR, Gallagher JA, Russell RG: Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118:2445-9, 1986
59. Andress DL, Pandian MR, Endres DB, Kopp JB: Plasma insulin-like growth factors and bone formation in uremic hyperpathyroidism. Kidney Int 36:471-477, 1989
60. Canalis E, Centrella M, Burch W, McCarthy TL: Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 83:60-65, 1989
61. 3 and human bone-derived cells in vitro: Effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology 119:1776-1785, 1986
62. Skjodt H, Gallagher JA, Beresford JN, Couch M, Poser JW, Russell RGG: Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. J Endocrinol 105:391-396, 1985
63. Andress DL, Howard GA, Brinbaum RS: Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 39:942-945, 1991